A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)

This publication has 17 references indexed in Scilit:

• The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database
  Lung Cancer, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2004
• O-188 Encouraging activity and durable responses demonstrated by the epithelial growth factor receptor-tyrosine kinase inhibitor, Erlotinib (Tarceva TM, OSI774), in patients with advanced bronchioloalveolar (BAC) cell carcinoma
  Lung Cancer, 2003
• O-187 ZD1839 (iressa) in advanced bronchioloalveolar carcinoma (BAC): A preliminary report of SWOG SO126
  Lung Cancer, 2003
• Prognostic significance of percentage of bronchioloalveolar pattern in adenocarcinomas of the lung
  Annals of Diagnostic Pathology, 2001
• Bronchoalveolar carcinoma: Clinical, radiologic, and pathologic factors and survival
  The Journal of Thoracic and Cardiovascular Surgery, 1999
• Relation of bronchioloalveolar carcinoma to tobacco.
  BMJ, 1992
• Bronchoalveolar carcinoma: Factors affecting survival
  The Annals of Thoracic Surgery, 1991